Technical analysis of Moleculin Biotech, Inc. (MBRX): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs.
Price Performance
| 1 month | +21.29% |
| 3 months | -74.31% |
| Year-to-date | -77.64% |
| 1 year | -92.49% |
| 3 years | -99.49% |
| 5 years | -99.94% |
52-Week Range
| 52-week High | $15.75 |
| 52-week Low | $0.16 |
| Avg Volume (90d) | 1.0M |
Technical Indicators
| SMA 50 | $1.11 |
| SMA 200 | $2.72 |
| 30-day Volatility (annualised) | 97.4% |
| Price vs SMA 50 | -33.1% |
| Price vs SMA 200 | -72.8% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $11.64 | |
| 2025-11 | $6.82 | -41.4% |
| 2025-12 | $3.31 | -51.5% |
| 2026-01 | $4.29 | +29.6% |
| 2026-02 | $2.39 | -44.3% |
| 2026-03 | $2.29 | -4.2% |
| 2026-04 | $2.56 | +11.8% |
| 2026-05 | $2.79 | +9.0% |
| 2026-06 | $2.79 | +0.0% |
| 2026-07 | $0.40 | -85.7% |
| 2026-08 | $0.64 | +61.2% |
| 2026-09 | $0.74 | +14.8% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $0.74 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.37 |
| EV / EBITDA | 0.10 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 0.94 |